A Phase 1 interventional study of MK-8527 in Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.
Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 25th largest by enrollment, is one of 2 that started in 2024, is one of 25 in phase 1, and was the 27th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 18–80 · Healthy volunteers
Merck Sharp & Dohme LLC
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 26 across the 32 interventional studies. Of the 29 that completed or were terminated, 17 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
2 of the studies in Renal Insufficiency by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07734610Merck Sharp & Dohme LLCA Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027) | 2027-02-01 |
| NCT07922174Merck Sharp & Dohme LLCA Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) | 2027-08-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI) on the pharmacokinetics (PK), safety, and tolerability of MK-8527. There will be no hypothesis testing in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Moderate and Severe RI
Healthy
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
All participants
Moderate and Severe RI
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with moderate renal impairment receive a single dose of MK-8527 on Day 1.
Drug: MK-8527
Participants with severe renal impairment receive a single dose of MK-8527 on Day 1.
Drug: MK-8527
Healthy participants receive a single dose of MK-8527 on Day 1.
Drug: MK-8527
Oral Capsule
Area Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-8527 in Plasma
Blood samples were collected at pre-specified time points to determine the AUC0-last of MK-8527 in participant's plasma. AUC0 to last of MK-8527 was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration. AUC0-last was calculated using noncompartmental analysis.
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma
Blood samples were collected at pre-specified time points to determine the AUC0-inf of MK-8527 in participant's plasma. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest,last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Maximum Concentration (Cmax) of MK-8527 in Plasma
Blood samples were collected at pre-specified time points to determine the Cmax of MK-8527 in participant's plasma. Cmax was defined as the maximum observed concentration of MK-8527 in plasma after the administration of a given dose.
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Time to Maximum Concentration (Tmax) of MK-8527 in Plasma
Blood samples were collected at pre-specified time points to determine the tmax of MK-8527 in participant's plasma. Tmax of MK-8527 in plasma was determined by deriving the difference between the time of the blood draw associated with the Cmax and the time of study drug administration
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Apparent Terminal Half-life (t1/2) of MK-8527 in Plasma
Blood samples were collected at pre-specified time points to determine the t1/2 of MK-8527 in participant's plasma. t1/2 was defined as 0.693/Apparent terminal elimination rate constant (λz).
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Apparent Clearance (CL/F) of MK-8527 in Plasma
Blood samples were collected at pre-specified time points to determine the CL/F of MK-8527 in participant's plasma. CL/F was defined as dose/(AUC0-inf).
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-8527 in Plasma
Blood samples were collected at pre-specified time points to determine the Vz/F of MK-8527 in participant's plasma. Vz/F of MK-8527 in plasma was determined using the formula Dose/(AUC0-inf × λz).
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 29 days
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 29 days
AUC0-last of MK-8527-triphosphate (TP) in Peripheral Blood Mononuclear Cells (PBMCs)
Blood samples were collected at pre-specified time points to determine the AUC0-last of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. AUC0 to last of MK-8527 was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration.
Time frame: Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose
AUC0-inf of MK-8527-TP in PBMCs
Blood samples were collected at pre-specified time points to determine the AUC0-inf of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest,last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.
Time frame: Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose
Cmax of MK-8527-TP in PBMCs
Blood samples were collected at pre-specified time points to determine the Cmax of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Cmax was defined as the maximum observed concentration of MK-8527-TP after the administration of a given dose.
Time frame: Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose
Concentration at 168 Hours (C168) of MK-8527-TP in PBMCs
Blood samples were collected at pre-specified time points to determine the C168 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Geometric mean of C168 of MK-8527-TP in PBMCs was determined.
Time frame: 168 hours post dose
Concentration at 672 Hours (C672) of MK-8527-TP in PBMCs in Participants With Moderate and Severe Renal Impairment
Blood samples were collected at pre-specified time points to determine the C672 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Geometric mean of C672 of MK-8527-TP in PBMCs was determined.
Time frame: 672 hours post dose
C672 of MK-8527-TP in PBMCs in Healthy Participants
Blood samples were collected at pre-specified time points to determine the C672 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Since ≤ 50% of healthy participants had BLQ values, the BLQ value was set to zero and the median, minimum, and maximum was reported for C672.
Time frame: 672 hours post dose
Tmax of MK-8527-TP in PBMCs
Blood samples were collected at pre-specified time points to determine the Tmax of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Tmax of MK-8527-TP was determined by deriving the difference between the time of the blood draw associated with the Cmax and the time of study drug administration
Time frame: Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose
T1/2 of MK-8527-TP in PBMCs
Blood samples were collected at pre-specified time points to determine the t1/2 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. t1/2 was defined as 0.693/Apparent terminal elimination rate constant (λz).
Time frame: Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose
| Milestone | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Started | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Number of Participants Who Experience One or More Adverse Events (AEs) | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Number of Participants Who Discontinue Study Due to an AE | 0 | 0 | 0 |
Blood samples were collected at pre-specified time points to determine the AUC0-last of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. AUC0 to last of MK-8527 was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration.
| pmol*hr/10^6 cells | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| AUC0-last of MK-8527-triphosphate (TP) in Peripheral Blood Mononuclear Cells (PBMCs) | 217 ± 37.2 | 493 ± 51.6 | 588 ± 37.6 |
Blood samples were collected at pre-specified time points to determine the AUC0-inf of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest,last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.
| pmol*hr/10^6 cells | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| AUC0-inf of MK-8527-TP in PBMCs | 235 ± 35.9 | 468 ± 27.5 | 552 ± 5.9 |
Blood samples were collected at pre-specified time points to determine the Cmax of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Cmax was defined as the maximum observed concentration of MK-8527-TP after the administration of a given dose.
| pmol/10^6 cells | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Cmax of MK-8527-TP in PBMCs | 1.77 ± 28.4 | 3.82 ± 78.4 | 3.18 ± 14.7 |
Blood samples were collected at pre-specified time points to determine the C168 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Geometric mean of C168 of MK-8527-TP in PBMCs was determined.
| pmol/10^6 cells | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Concentration at 168 Hours (C168) of MK-8527-TP in PBMCs | 0.470 ± 39.3 | 0.948 ± 118.9 | 1.03 ± 46.0 |
Blood samples were collected at pre-specified time points to determine the C672 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Geometric mean of C672 of MK-8527-TP in PBMCs was determined.
| pmol/10^6 cells | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Concentration at 672 Hours (C672) of MK-8527-TP in PBMCs in Participants With Moderate and Severe Renal Impairment | — | 0.183 ± 54.1 | 0.248 ± 50.7 |
Blood samples were collected at pre-specified time points to determine the C672 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Since ≤ 50% of healthy participants had BLQ values, the BLQ value was set to zero and the median, minimum, and maximum was reported for C672.
| pmol/10^6 cells | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| C672 of MK-8527-TP in PBMCs in Healthy Participants | 0.0673 (0.00 to 0.0874) | — | — |
Blood samples were collected at pre-specified time points to determine the Tmax of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Tmax of MK-8527-TP was determined by deriving the difference between the time of the blood draw associated with the Cmax and the time of study drug administration
| hr | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Tmax of MK-8527-TP in PBMCs | 23.08 (11.92 to 23.92) | 23.92 (23.53 to 167.07) | 23.01 (23.00 to 23.53) |
Blood samples were collected at pre-specified time points to determine the t1/2 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. t1/2 was defined as 0.693/Apparent terminal elimination rate constant (λz).
| hr | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| T1/2 of MK-8527-TP in PBMCs | 170 ± 44.1 | 212 ± 24.6 | 251 ± 36.2 |
Blood samples were collected at pre-specified time points to determine the AUC0-last of MK-8527 in participant's plasma. AUC0 to last of MK-8527 was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration. AUC0-last was calculated using noncompartmental analysis.
| nM·hr | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Area Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-8527 in Plasma | 769 ± 21.4 | 1160 ± 24.6 | 1430 ± 20.1 |
Blood samples were collected at pre-specified time points to determine the AUC0-inf of MK-8527 in participant's plasma. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest,last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.
| nM·hr | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma | 918 ± 22.2 | 1640 ± 30.0 | 2060 ± 24.0 |
Blood samples were collected at pre-specified time points to determine the Cmax of MK-8527 in participant's plasma. Cmax was defined as the maximum observed concentration of MK-8527 in plasma after the administration of a given dose.
| nM | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Maximum Concentration (Cmax) of MK-8527 in Plasma | 112 ± 25.7 | 161 ± 48.9 | 91.7 ± 22.1 |
Blood samples were collected at pre-specified time points to determine the tmax of MK-8527 in participant's plasma. Tmax of MK-8527 in plasma was determined by deriving the difference between the time of the blood draw associated with the Cmax and the time of study drug administration
| hr | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Time to Maximum Concentration (Tmax) of MK-8527 in Plasma | 0.75 (0.52 to 1.53) | 0.75 (0.50 to 1.00) | 0.99 (0.25 to 6.00) |
Blood samples were collected at pre-specified time points to determine the t1/2 of MK-8527 in participant's plasma. t1/2 was defined as 0.693/Apparent terminal elimination rate constant (λz).
| hr | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Apparent Terminal Half-life (t1/2) of MK-8527 in Plasma | 84.2 ± 14.1 | 118 ± 32.5 | 113 ± 38.0 |
Blood samples were collected at pre-specified time points to determine the CL/F of MK-8527 in participant's plasma. CL/F was defined as dose/(AUC0-inf).
| Liter/hr | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Apparent Clearance (CL/F) of MK-8527 in Plasma | 21.2 ± 22.2 | 11.8 ± 30.0 | 9.45 ± 24.0 |
Blood samples were collected at pre-specified time points to determine the Vz/F of MK-8527 in participant's plasma. Vz/F of MK-8527 in plasma was determined using the formula Dose/(AUC0-inf × λz).
| Liter | Healthy | Moderate Renal Impairment | Severe Renal Impairment |
|---|---|---|---|
| Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-8527 in Plasma | 2570 ± 29.7 | 2020 ± 27.0 | 1540 ± 36.5 |
Collected over up to approximately 30 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Moderate Renal Impairment | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Severe Renal Impairment | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Healthy | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Age, Continuous(Years) | Healthy | Moderate Renal Impairment | Severe Renal Impairment | Total |
|---|---|---|---|---|
| Mean | 60.0 ± 5.25 | 63.7 ± 6.44 | 67.8 ± 5.88 | 63.8 ± 6.43 |
| Sex: Female, Male(Participants) | Healthy | Moderate Renal Impairment | Severe Renal Impairment | Total |
|---|---|---|---|---|
| Female | 3 | 2 | 3 | 8 |
| Male | 3 | 4 | 3 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Healthy | Moderate Renal Impairment | Severe Renal Impairment | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 5 | 6 | 6 | 17 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Healthy | Moderate Renal Impairment | Severe Renal Impairment | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 4 | 5 | 12 |
| White | 3 | 2 | 1 | 6 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Baseline estimated glomerular filtration rate (eGFR)(mL/min) | Healthy | Moderate Renal Impairment | Severe Renal Impairment | Total |
|---|---|---|---|---|
| Mean | 100.758 ± 9.9802 | 44.292 ± 8.8361 | 22.875 ± 5.0729 | 55.975 ± 34.6775 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2024 to primary completion in Jan 2025, 7 months.
Results were first posted in Feb 2026, 1 year after primary completion.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alimatravir